Antidepressive effects of targeting ELK-1 signal transduction.

Depression, a devastating psychiatric disorder, is a leading cause of disability worldwide. Current antidepressants address specific symptoms of the disease, but there is vast room for improvement 1 . In this respect, new compounds that act beyond classical antidepressants to target signal transduction pathways governing synaptic plasticity and cellular resilience are highly warranted2-4. The extracellular signal-regulated kinase (ERK) pathway is implicated in mood regulation5-7, but its pleiotropic functions and lack of target specificity prohibit optimal drug development. Here, we identified the transcription factor ELK-1, an ERK downstream partner 8 , as a specific signaling module in the pathophysiology and treatment of depression that can be targeted independently of ERK. ELK1 mRNA was upregulated in postmortem hippocampal tissues from depressed suicides; in blood samples from depressed individuals, failure to reduce ELK1 expression was associated with resistance to treatment. In mice, hippocampal ELK-1 overexpression per se produced depressive behaviors; conversely, the selective inhibition of ELK-1 activation prevented depression-like molecular, plasticity and behavioral states induced by stress. Our work stresses the importance of target selectivity for a successful approach for signal-transduction-based antidepressants, singles out ELK-1 as a depression-relevant transducer downstream of ERK and brings proof-of-concept evidence for the druggability of ELK-1.

Opposing alterations in excitation and inhibition of layer 5 medial prefrontal cortex pyramidal neurons following neonatal ventral hippocampal lesion.

Cognitive abnormalities in schizophrenia reflect deficits in prefrontal cortical function, which could be related to attrition of dendritic structures of prefrontal cortical neurons. Schizophrenia-related prefrontal deficits have been modeled in postpubertal neonatal ventral hippocampal lesioned (NVHL) rats, which displayed a loss of dendritic complexity and spines in layer 3 pyramidal neurons in the medial prefrontal cortex (mPFC). The influence of dendritic attrition on synaptic function and neuronal excitability in the mPFC remains poorly understood. Here, we performed electrophysiological recordings of layer 5 mPFC pyramidal neurons from postpubertal (postnatal 40-60 days) NVHL rats and sham-operated controls. We found that the dendritic length, complexity, and spine density of neurobiotin-labeled layer 5 mPFC pyramidal neurons in NVHL rats were significantly lower than those in sham-operated rats. However, the excitability of layer 5 mPFC pyramidal neurons remained unchanged after NVHL. We found no significant changes in the expression of vesicular glutamate and γ-aminobutyric acid transporters after NVHL. Intriguingly, NVHL increased the amplitude of action potential-independent miniature excitatory postsynaptic currents and decreased the frequency of miniature inhibitory postsynaptic currents. These opposing alterations in excitatory and inhibitory synapses, possibly shifting basal synaptic activity toward increased excitation, could be cellular substrates for mPFC functional deficits reported in NVHL rats.